Diabetes

How Kaiser Permanente Got Biosimilars Into Play

July 29th 2020

By Tony Hagen

Article

Biologics are not cheap, and if you can get biosimilars into the hands of patients, you’ve got something going. A strategist describes the step-by-step process that made this possible at Kaiser Permanente.

Interview: Medicines for Europe Reports on EU Biosimilar Success

July 27th 2020

By Tony Hagen

Article

The Center for Biosimilars® (CfB) spoke with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, about their scorecard report for biosimilar access in European markets.

Trump Moves Ahead With Drug Import Plan

July 25th 2020

By Skylar Jeremias

Article

President Trump signed 4 executive orders that would lower prices of prescriptions medications including insulin products and cancer medicines.

Biocon Reports Strong Quarter for Its Biosimilars Unit

July 24th 2020

By Tony Hagen

Article

For Biocon, overall revenues were up during the fiscal quarter that just ended, driven by strong revenues in its biosimilars and generics operations.

Biocon Biologics Pairs Digital Therapeutics With Insulin

July 22nd 2020

By Tony Hagen

Article

In a deal with Voluntis, Biocon Biologics aims to extend the appeal of its insulin products by offering a digital titration device for self-management of insulin dosage.

New Battleground Shaping Up Over Insulin Deliverables

July 20th 2020

By Tony Hagen

Article

With insulin originator product patents expiring, drug companies are seeking to extend exclusivities via patents on injectors and other delivery products.

Analysis of FDA-Licensed Biosimilars: Time for a Paradigm Shift

July 11th 2020

By Sarfaraz K. Niazi, PhD

Article

Now is the time for the FDA to lead again in revising the biosimilar development guidance by eliminating all animal toxicology studies, and replacing them with larger-species pharmacokinetic (PK) studies, allowing the conduct of human PK studies using novel clinical protocols to combine the PK/pharmacodynamic/immunogenicity testing in a single study, and, where possible, avoid these studies if an in-silico approach can provide the confidence of pharmacologic similarity.

Biocon Seeks to Take Biosimilars Unit Public by 2023

July 8th 2020

By Skylar Jeremias

Article

Biocon is planning to list its biosimilar entity, Biocon Biologics, on the capital markets in the next few years. Although this move will allow the entity to expand on current projects, it also raises questions about whether it will be successful.

Doctors Manage Insulin Degludec-to-Glargine Transition Poorly, ADA Study Says

June 20th 2020

By Tony Hagen

Article

There is much inconsistency in the way physicians transition patients from insulin degludec to insulin glargine upon hospital admission, leading to higher risk especially for patients with type 1 diabetes, according to a study presented at the American Diabetes Association 80th Scientific Sessions online conference.

FDA Approves Eli Lilly Insulin Lispro Formulation

June 18th 2020

By Tony Hagen

Article

Eli Lilly gets FDA approval for a new formulation of insulin lispro and offers it at the out-of-pocket cap of $35 for a monthly supply for patients with or without insurance.